NVO changes
Pick any two versions below to diff them.
- Price
- $38.64 → $41.09(+6.3%)
- Next earnings
- Nov 4, 2026 → Feb 3, 2027
- Thesis
- The market prices Novo at a discount because it fears Novo is losing the obesity-drug race to Eli Lilly. Lilly's tirzepatide beat semaglutide head-to-head. Lilly has already overtaken Novo in ex-US GLP-1 market share, a class of diabetes and weight-loss drugs. added: Even after three upward revisions, Novo's own 2026 guidance removed: still points added: only to added: adjusted sales and added: operating profit removed: coming in flat to down for the year, even after two upward revisions. added: between a 2% fall and a 2% rise at constant exchange rates. Generic versions of semaglutide are also arriving faster than expected outside the US, with Canada approving a first generic Ozempic in April 2026 and a first generic Wegovy in June 2026. At its September 2026 Capital Markets Day, management set an ambition for revenue growth from 2026 to 2030 in line with large pharmaceutical peers. That told the market that Novo itself expects only average industry growth from here. For the gap to close, two things need to happen together. The Wegovy pill needs to keep growing faster than the older injectable franchise removed: shrinks. added: shrinks; in Q3 2026 it sold DKK 5.4 billion, while Wegovy injectable sales fell 2% and Ozempic sales fell 5% at constant exchange rates. CagriSema, Novo's next obesity and diabetes drug, needs to reach the market and take share back from Lilly. In the REDEFINE 4 obesity trial, CagriSema did not show weight loss as large as the highest dose of tirzepatide. It beat only the lowest dose of tirzepatide, in a diabetes trial. So the CagriSema launch must win patients with other qualities, such as tolerability, price and supply. An FDA obesity decision on CagriSema is due in the fourth quarter of removed: 2026. added: 2026, and Novo prepares a US launch in early 2027. New CEO Mike Doustdar is also cutting about 9,000 jobs to fund the turnaround. If the FDA approves CagriSema on schedule and its launch goes well alongside continued Wegovy pill growth, the gap could start closing over the next two to four quarters. The removed: Q3 2026 report on November 4, 2026 added: CagriSema decision and the full-year report on February 3, 2027 give the next evidence. The US list price cut on January 1, 2027 tests whether more patients make up for the lower price. If Lilly keeps taking share faster than Novo can respond, or generic competition spreads to more markets, the discount could persist well beyond 2026. Management's own targets no longer assume a return to Novo's old growth rate.
- Risks
- Eli Lilly's tirzepatide (Zepbound and Mounjaro) beat Novo's semaglutide head-to-head on weight loss and has overtaken Novo in ex-US GLP-1 market share. If Lilly keeps taking share in obesity, Novo's main growth driver keeps shrinking. Full-year 2026 guidance, even after removed: two added: three upward revisions during the year, removed: still points to adjusted sales and operating profit removed: coming in flat to down 6% added: between a 2% fall and a 2% rise at constant exchange rates versus removed: 2025. added: 2025 (November 4, 2026). Even the best case is added: almost a flat removed: year. added: year, and the US list price cut on January 1, 2027 lowers the price per prescription. Semaglutide's patent has already lapsed in Canada and China, and Canada approved a first generic Ozempic in April 2026 and a first generic Wegovy in June 2026. Its main US compound patent does not expire until 2032, but faster-than-expected generic erosion in other large markets would cut into sales sooner than modeled. The US pricing deal sets a $350 monthly cash price on TrumpRx in exchange for broader Medicare and Medicaid coverage. On January 1, 2027, the US list prices of Wegovy and Ozempic go down to $675 a month, about 50% lower for Wegovy and 35% lower for Ozempic. Novo says that this cut will reduce 2027 cash flow. If volume growth does not offset the lower price per prescription, US revenue growth could disappoint. Novo is going through a leadership and board overhaul during a critical competitive stretch: a new CEO since August 2025, a new chairman since November 2025, and more than half the board turning over. That much change at once adds execution risk. Pipeline drugs like CagriSema still need regulatory approval (an FDA obesity decision is due in Q4 2026) before they can offset any further erosion in Ozempic and Wegovy. A delay or rejection would remove a key reason to expect the discount to close. The Novo Nordisk Foundation controls about 77% of the votes through Novo Holdings, so public shareholders can never gain control of the company or force a takeover, regardless of where the share price trades.
- Balance sheet
- Cash: DKK removed: 45.0B added: 46.4B Debt: DKK removed: 131.5B added: 126.1B Net debt: DKK removed: 86.5B added: 79.7B EBITDA, last 12 months: DKK removed: 142.5B added: 148.5B Net debt / EBITDA: removed: 0.6× added: 0.5× (low) Interest cover: removed: 24× added: 30× Undrawn credit line: DKK 24.4B Debt due within 12 months: DKK removed: 17.0B added: 15.0B Ratings: S&P AA (stable outlook), Moody's Aa3 (stable outlook) Novo Nordisk had almost no net debt until 2024. Then it borrowed to buy three fill-finish plants from its controlling shareholder Novo Holdings, which came with the Catalent deal, and later to buy Akero Therapeutics. Debt excludes leases. Most of it is fixed-rate Eurobonds under a EUR 30 billion EMTN programme. There are also some Swiss franc bonds, bank loans and commercial paper. removed: Cash includes added: At September 30, 2026, borrowings without leases were DKK removed: 0.5 billion added: 126.1 billion, and cash at bank and marketable securities were DKK 46.4 billion, of added: which DKK 2.2 billion were marketable securities. added: Novo's net debt was DKK 79.7 billion at September 30, 2026, down from DKK 95.4 billion at December 31, 2025. EBITDA covers the 12 months to removed: June added: September 30, removed: 2026. added: 2026, and is an estimate from Novo's reported EBITDA growth. It leaves out a one-time, non-cash DKK 26.8 billion reversal of a US rebate provision in the first quarter of 2026. Interest cover is adjusted operating profit over interest paid in the first removed: half added: nine months of 2026. The undrawn credit is a EUR 3.3 billion committed facility that matures in 2030 (amount at December 31, 2025). Debt due within 12 months is an estimate without leases. In the first removed: half added: nine months of 2026, free cash flow was DKK removed: 55.3 added: 83.8 billion. It paid for DKK removed: 35.3 added: 51.9 billion of dividends and DKK removed: 5.9 added: 10.0 billion of share buybacks. The buybacks are part of a DKK 15 billion programme that runs to February removed: 2027. added: 2027; by November 2, 2026, Novo had used DKK 11.6 billion of it. The debt does not limit Novo's choices. Falling profits would cut buybacks and acquisitions before they put the high credit ratings at risk. As of removed: Jun added: Sep 30, 2026.
- Checkpoints
- Nov 4, 2026: Q3 2026 results: Wegovy pill growth and guidance. removed: Pending. added: Passed. Watch: Wegovy pill sales that grow faster than injectable semaglutide shrinks and guidance held or raised pass; a guidance cut or a stall in pill growth fails. added: Outcome: Wegovy pill sales were DKK 5,394 million in Q3 2026, almost equal to its DKK 5,474 million in the first half, far more than the fall in Wegovy injectable and Ozempic sales, and Novo raised its 2026 outlook to -2% to +2%. Q4 2026 (estimate): FDA decision on CagriSema for obesity. Pending. Watch: An approval with a clean label in Q4 2026 passes; a rejection, a complete response letter or a delay into 2027 fails. Feb 3, 2027: Full-year 2026 results and 2027 outlook. Pending. Watch: A 2027 outlook for sales and operating profit growth at constant exchange rates, after the US list price cut to $675, passes; a second year of falling sales or profit fails.
- Recent events
- added: Nov 4, 2026: Novo reported Q3 2026 results. Adjusted sales rose 4% at constant exchange rates to DKK 79,195 million, and both US and International Operations grew. Obesity sales rose 22%, and the Wegovy pill sold DKK 5,394 million. Adjusted operating profit rose 27% to DKK 31,720 million, against Q3 2025 costs of DKK 9 billion for the job cuts. Reported operating profit fell 9% after DKK 8.7 billion of non-cash impairments, for ziltivekimab, whose Phase 3 heart trials failed, and for the manufacturing network. Novo raised its 2026 outlook for adjusted sales and adjusted operating profit growth to -2% to +2% at constant exchange rates. Oct 2, 2026: The FDA extended its review of denecimig, Novo's new hemophilia A medicine, because a manufacturing site needs repairs. The FDA set no new decision date and found no problems with the clinical data. Novo aims for a US launch in the first half of 2027 and says that its 2026 outlook does not change. In the EU, an advisory committee recommended approval on September 17, 2026. Sep 29, 2026: Novo agreed to license HRS-1596 from Hengrui Pharma. HRS-1596 is an early-stage, once-weekly oral GLP-1/GIP obesity pill. Novo pays $300 million upfront. The deal can reach $2.6 billion with milestones. It excludes mainland China, Hong Kong, Macao and Taiwan. It needs US antitrust clearance and should close in Q4 2026. It had not closed by October 12, 2026. Sep 21, 2026: At its Capital Markets Day, Novo set 2030 ambitions for revenue growth in line with a group of large pharmaceutical peers (not above them), broadly stable operating margins, and serving more than 60 million patients globally. The stock fell about 7.7% that day. The same day, Novo reported Phase 3 data from REIMAGINE 5 in people with type 2 diabetes. CagriSema gave more weight loss than the lowest dose (5 mg) of Eli Lilly's tirzepatide: 12.4% vs 9.1%. Aug 4, 2026: Novo reported Q2 2026 results: adjusted sales of DKK 78,488 million, up 7% at constant exchange rates, and adjusted operating profit of DKK 33,389 million, up 11%. Management raised full-year 2026 guidance to 0% to -6% growth (from -4% to -12%) for both adjusted sales and operating profit, citing higher expected sales of its GLP-1 medicines. Dec 22, 2025: The FDA approved the Wegovy pill (oral semaglutide, 25 mg), the first oral GLP-1 medicine approved for weight management. It launched in the US on January 5, 2026. Nov 6, 2025: Novo agreed to a pricing deal with the Trump administration, cutting Ozempic and Wegovy prices for Medicare, Medicaid, and a new consumer website, TrumpRx.gov, with Medicare set to begin covering obesity drugs for some patients from mid-2026, plus a three-year tariff exemption. Oct 21, 2025: Amid a board dispute over the pace of change, Chairman Helge Lund agreed to step down. Novo Holdings, controlled by the Novo Nordisk Foundation, said former Novo Nordisk CEO Lars Rebien Sørensen would become the new chairman, with more than half the board set to turn over. Shareholders elected him at an extraordinary general meeting on November 14, 2025. Oct 9, 2025: Novo agreed to acquire Akero Therapeutics for up to $5.2 billion ($54 per share in cash plus a $6 per share contingent payment), adding efruxifermin, a Phase 3 drug for the liver disease MASH. The deal closed in December 2025. Sep 10, 2025: New CEO Mike Doustdar, a little over a month into the role, announced plans to cut about 9,000 jobs (about 11% of the workforce) to save roughly DKK 8 billion ($1.3 billion) a year by the end of 2026.